Clinical development of immunotherapies for HER2⁺ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.

ABSTRACT: Human epidermal growth factor receptor 2-positive (HER2⁺) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2⁺ breast cancer. In this narrative review, we summarize advances in the understanding of immune system interactions, examine clinical developments, and suggest rationales for future investigation of immunotherapies for HER2⁺ breast cancer. Complex interactions have been found between different branches of the immune system, HER2⁺ breast cancer, and targeted treatments (approved and under investigation). A new wave of immunotherapies, such as novel HER2-directed mAbs, antibody drug conjugates, vaccines, and adoptive T-c

SUBMITTER: Costa RLB 

PROVIDER: S-EPMC7067811 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature